Applied Clinical Trials-03-01-2023

The responsibility of increasing diversity falls on every stakeholder in the clinical trial value chain.

Survey examines trial enrollment motivation among diverse populations.

Advancing responsible AI innovation to help resolve patient disparities.

Outlining new approaches and resources to help ignite progress in this area.

Self-determined eligibility and the influence of clinical care challenge this flawed figure.

EU Medical Device Regulation must be followed carefully as it leaves room for interpretation.

Industry sees high increase in the use of QTLs.

Panel discussion at SCOPE highlights strategies to increase diversity in clinical trials.

Reformed EMA looks to tackle challenges in drug development, pediatric medicines, and unmet medical need.

Noise in modern day life may be interfering with our ability to learn.

Click the title above for a link to open the Applied Clinical Trials March 2023 issue in an interactive PDF format.

Sanjay Shukla, MD, MS, CEO of aTyr Pharma, discusses the company's clinical operations and ongoing Phase III study for pulmonary sarcoidosis.

With industry’s uneven track record in patient representation, sponsors now mandated to submit Diversity Action Plans (DAPs) to FDA for Phase III and pivotal studies.

Researchers face various challenges that cause their clinical trials to fail to meet enrollment timelines, among other issues.